124 related articles for article (PubMed ID: 9395032)
1. Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy.
Bloomfield CD; Herzig GP; Peterson BA; Wolff SN
Cancer; 1997 Dec; 80(11 Suppl):2186-90. PubMed ID: 9395032
[TBL] [Abstract][Full Text] [Related]
2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
3. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
Ohno R; Kobayashi T; Tanimoto M; Hiraoka A; Imai K; Asou N; Tomonaga M; Tsubaki K; Takahashi I; Kodera Y
Cancer; 1993 Jun; 71(12):3888-95. PubMed ID: 8508355
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
[TBL] [Abstract][Full Text] [Related]
6. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
10. Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Schiller G; Gajewski J; Lee M; Ho W; Territo M; Champlin R
Leuk Lymphoma; 1994 Sep; 15(1-2):85-90. PubMed ID: 7858506
[TBL] [Abstract][Full Text] [Related]
11. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
Rees JK; Gray RG; Wheatley K
Br J Haematol; 1996 Jul; 94(1):89-98. PubMed ID: 8757514
[TBL] [Abstract][Full Text] [Related]
12. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
[TBL] [Abstract][Full Text] [Related]
13. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
14. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
15. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
[TBL] [Abstract][Full Text] [Related]
16. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
17. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Moore JO; George SL; Dodge RK; Amrein PC; Powell BL; Kolitz JE; Baer MR; Davey FR; Bloomfield CD; Larson RA; Schiffer CA
Blood; 2005 May; 105(9):3420-7. PubMed ID: 15572587
[TBL] [Abstract][Full Text] [Related]
18. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Bishop JF; Matthews JP; Young GA; Bradstock K; Lowenthal RM
Leuk Lymphoma; 1998 Jan; 28(3-4):315-27. PubMed ID: 9517503
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Jehn U
Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
